Sumitomo Chemical Company, Limited
Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 [IFRS] (Consolidated)
For the second quarter of the fiscal year ending March 2027 (consolidated), revenue was 1,172,800 million yen (increase of 7.1% year-over-year), core operating profit was 144,531 million yen, operating profit was 138,058 million yen, and net income attributable to owners of parent for the interim period was 82,875 million yen. Full-year forecasts were revised upward to revenue 2,490,000 million yen, core operating profit 270,000 million yen, operating profit 215,000 million yen, and net income 90,000 million yen. Prime Polymer was newly added as a consolidated subsidiary. Interim dividend is expected to be 8 yen, with a full-year forecast of 17 yen.
Key Figures
- Revenue: 1,172,800 million yen (7.1% increase YoY)
- Core Operating Profit: 144,531 million yen
- Operating Profit: 138,058 million yen
- Net Income Attributable to Owners of Parent (Interim): 82,875 million yen
- Full-year Forecast: Revenue 2,490,000 million yen, Core Operating Profit 270,000 million yen, Net Income 90,000 million yen
AI要約
Overview of Results
In the second quarter (interim period) of the fiscal year ending March 2027, Sumitomo Chemical Company, Limited reported consolidated revenue of 1,172,800 million yen, a 7.1% increase year-over-year. Core operating profit was 144,531 million yen and operating profit was 138,058 million yen. Segment contributions included Agro & Life Solutions and others. There was a change in IFRS application policy with no adjustments related to company name changes. An interim dividend of 8 yen is planned. Full-year forecasts were revised upward to revenue of 2,490,000 million yen, core operating profit of 270,000 million yen, operating profit of 215,000 million yen, and net income of 90,000 million yen.
Impact on Shareholders and Future Outlook
The addition of Prime Polymer Co., Ltd. as a newly consolidated entity led to changes in segment planning. The upward revision to the full-year forecast is attributed to expected increased shipments of semiconductor materials in ICT & Mobility Solutions, progress in Essential & Green Materials businesses, and expansion of Sumitomo Pharma in the U.S. Consolidated financial position: total assets 3,626,081 million yen, liabilities 2,143,455 million yen, and equity 1,482,626 million yen. There is no mention of treasury stock activity in the main text.
Revenue Trend
Operating Profit Trend
Segment Revenue Breakdown
Comparison of Guidance and Results
Sumitomo Chemical Company, Limited
Company overview · Stock price · Financial data · All IR
